Seedy19: A 35x Return From Biotech Investing

C.D. entered biotech investing by chance, working at a pharmaceutical company during his Big Four consulting rotation that was extended due to COVID. Without a science background, he spent considerable time learning from others and reading to understand the space. He emphasizes that biotech investing is fundamentally different from other sectors because binary clinical trial outcomes create massive short-term valuation swings based on real drug assets and fundamentals, not speculative momentum.

His 35x return came from a diversified strategy combining common stock positions, covered calls on positions he believed had run too far, and put-writing where he felt comfortable with downside floors. He avoided call options due to timing risk and preferred to write puts because the worst case—assignment at desired entry levels—was acceptable. He notes that as a generalist investor, AI tools have democratized biotech analysis, allowing anyone to understand complex trial data and molecular structures without a scientific background.

C.D. illustrates his approach through specific case studies. With Urogen, he identified a stock trading at $3.50 that the market had mispriced following a split ODAC vote, despite historical precedent showing such votes typically lead to FDA approval. He structured a collar trade (long equity, short calls, long puts) that returned 3x. With Abivax, he identified a company with one week of cash runway but sitting on a validated asset from Phase 2 data, where the downside was capped at 95-100% loss while upside was unlimited—a bet that ultimately returned 2000%. He emphasizes that finding these asymmetrical risk-reward opportunities is the core of his strategy.

He explains that biotech's unique characteristic is having a built-in exit through M&A, unlike tech sectors where exit timing is ambiguous. Most small-to-mid-cap biotech companies will eventually be acquired by large pharmaceuticals at predictable multiples (2-3x sales), creating a natural selling point. This contrasts with cases like RevMed at $40 billion with zero revenue, which he argues is completely justified given the blockbuster potential of their Pan-RAS inhibitor.

On finding ideas, C.D. recommends starting by reviewing holdings of top specialist biotech hedge funds through their 13F filings, then analyzing the corporate decks using AI tools for interpretation. He doesn't rely on screeners but rather maintains a watchlist of 40-50 companies while only actively investing in 5-10, allowing him to recognize opportunities when complementary assets get acquired.

Regarding current opportunities, he identifies several hot spaces: neurological diseases (MDD, Alzheimer's), cardiovascular space, immunology (citing how atopic dermatitis evolved from a perceived niche to a $20+ billion market), rare diseases with gene therapy, and oncology. He argues AI's impact on biotech isn't a standalone trade but rather a tailwind that accelerates timelines—trials still require fixed durations and patient cohorts, so AI speeds the path to market rather than being the return itself.

On what's overhyped, C.D. notes that crowded shorts from the bear market had to cover during the 2024-2025 bull run, leaving many poor-quality assets with unjustified valuations. He personally stopped shorting after being badly wrong on Capricorn (6 to 30), recognizing headline risk in biotech makes shorting dangerous. However, he acknowledges short-selling remains important to the ecosystem to expose fraudulent companies, particularly referencing overhyped Alzheimer's companies that raised billions on unfounded promises.